For FSGS, angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are essential to reduce proteinuria and slow disease progression [36]. This evidence concerns the gene ACE and focal segmental glomerulosclerosis.